The DOI matches its Crossref record; 15 of the 23 references it cites were found in a registry or an index, and 8 are not checked yet.
Gene Expression Alterations in Prostate Cancer Predicting Tumor Aggression and Preceding Development of Malignancy
Abstract
Purpose: The incidence of prostate cancer is frequent, occurring in almost one-third of men older than 45 years. Only a fraction of the cases reach the stages displaying clinical significance. Despite the advances in our understanding of prostate carcinogenesis and disease progression, our knowledge of this disease is still fragmented. Identification of the genes and patterns of gene expression will provide a more cohesive picture of prostate cancer biology. Patients and Methods: In this study, we performed a comprehensive gene expression analysis on 152 human samples including prostate cancer tissues, prostate tissues adjacent to tumor, and organ donor prostate tissues, obtained from men of various ages, using the Affymetrix (Santa Clara, CA) U95a, U95b, and U95c chip sets (37,777 genes and expression sequence tags). Results: Our results confirm an alteration of gene expression in prostate cancer when comparing with nontumor adjacent prostate tissues. However, our study also indicates that the gene expression pattern in tissues adjacent to cancer is so substantially altered that it resembles a cancer field effect. Conclusion: We also found that gene expression patterns can be used to predict the aggressiveness of prostate cancer using a novel model.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Cluster analysis and display of genome-wide expression patterns
Eisen, M. B., Spellman, P. T., Brown, P. O., & Botstein, D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.25.14863 · Cited by 16,184
Golub, T. R., Slonim, D. K., Tamayo, P., Huard, C., Gaasenbeek, M., Mesirov, J. P., Coller, H., Loh, M. L., Downing, J. R., Caligiuri, M. A., et al. (1999) · Science · doi:10.1126/science.286.5439.531 · Cited by 11,516
Fundamentals of Biostatistics.
(1969) · Annals of Internal Medicine · doi:10.7326/0003-4819-70-4-873 · Cited by 4,575
Classical and Modern Regression With Applications.
Steinhorst, R. K., & Myers, R. H. (1988) · Journal of the American Statistical Association · doi:10.2307/2288958 · Cited by 3,690
Jemal, A., Murray, T., Samuels, A., Ghafoor, A., Ward, E., & Thun, M. J. (2003) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.53.1.5 · Cited by 3,275
Gene expression correlates of clinical prostate cancer behavior
Singh, D., Febbo, P. G., Ross, K., Jackson, D. G., Manola, J., Ladd, C., Tamayo, P., Renshaw, A. A., D'Amico, A. V., Richie, J. P., et al. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00030-2 · Cited by 2,512
Delineation of prognostic biomarkers in prostate cancer
Dhanasekaran, S. M., Barrette, T. R., Ghosh, D., Shah, R., Varambally, S., Kurachi, K., Pienta, K. J., Rubin, M. A., & Chinnaiyan, A. M. (2001) · Nature · doi:10.1038/35090585 · Cited by 1,673
Welsh, J. B., Sapinoso, L. M., Su, A. I., Kern, S. G., Wang‐Rodriguez, J., Moskaluk, C. A., Frierson, H. F., & Hampton, G. M. (2001) · PubMed · Cited by 856
Latulippe, É., Satagopan, J. M., Smith, A., Scher, H. I., Scardino, P. T., Reuter, V. E., & Gerald, W. L. (2002) · PubMed · Cited by 518
Cited by
Items 201–300 of 761
Plakophilins in Desmosomal Adhesion and Signaling
Hatzfeld, M., Wolf, A., & Keil, R. (2014) · Cell Communication & Adhesion · doi:10.3109/15419061.2013.876017 · Cited by 66
Utility of multispectral imaging in automated quantitative scoring of immunohistochemistry
Fiore, C., Bailey, D., Conlon, N., Wu, X., Martin, N., Fiorentino, M., Finn, S. P., Fall, K., Andersson, S., Andrén, O., et al. (2012) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2012-200734 · Cited by 62
Zhang, Y., Yuan, Y., Liang, P., Zhang, Z., Guo, X., Xia, L., Zhao, Y., Shu, X., Sun, S., Ying, Y., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17564 · Cited by 66
Copine-III interacts with ErbB2 and promotes tumor cell migration
Heinrich, C., Keller, C., Boulay, A., Vecchi, M., Bianchi, M., Sack, R., Lienhard, S., Duss, S., Hofsteenge, J., & Hynes, N. (2010) · Oncogene · doi:10.1038/onc.2009.456 · Cited by 58
Kim, K., Chadalapaka, G., Pathi, S. S., Jin, U.-H., Lee, J., Park, Y., Cho, S., Chintharlapalli, S. R., & Safe, S. H. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0181 · Cited by 61
Daves, M. H., Hilsenbeck, S. G., Lau, C. C., & Man, T. (2011) · BMC Medical Genomics · doi:10.1186/1755-8794-4-56 · Cited by 68
Systems biology approaches to investigating the roles of extracellular vesicles in human diseases
Gézsi, A., Kovács, Á. F., Visnovitz, T., & Buzás, E. I. (2019) · Experimental & Molecular Medicine · doi:10.1038/s12276-019-0226-2 · Cited by 65
Kelavkar, U. P., Harya, N. S., Hutzley, J., Bacich, D. J., Monzon, F. A., Chandran, U. R., Dhir, R., & O’Keefe, D. S. (2006) · Prostaglandins & Other Lipid Mediators · doi:10.1016/j.prostaglandins.2006.05.015 · Cited by 61
Self-citationCD38 Inhibits Prostate Cancer Metabolism and Proliferation by Reducing Cellular NAD+ Pools
Chmielewski, J. P., Bowlby, S. C., Wheeler, F. B., Shi, L., Sui, G., Davis, A. L., Howard, T. D., D'Agostino, R. B., Miller, L. D., Sirintrapun, S. J., et al. (2018) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0526 · Cited by 64
Molinaro, R. J., Jha, B. K., Malathi, K., Varambally, S., Chinnaiyan, A. M., & Silverman, R. H. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkl968 · Cited by 60
Essential role of JunD in cell proliferation is mediated via MYC signaling in prostate cancer cells
Elliott, B., Millena, A. C., Matyunina, L. V., Zhang, M., Zou, J., Wang, G., Zhang, Q., Bowen, N. J., Eaton, V., Webb, G., et al. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.02.005 · Cited by 61
Neeb, A., Wallbaum, S., Novac, N., Dukowic‐Schulze, S., Scholl, I., Schreiber, C., Schlag, P., Moll, J., Stein, U., & Sleeman, J. P. (2011) · Oncogene · doi:10.1038/onc.2011.535 · Cited by 59
Chen, Z., Yu, Y. P., Tao, J., Liu, S., Tseng, G. C., Nalesnik, M. A., Hamilton, R. L., Bhargava, R., Nelson, J. B., Pennathur, A., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2016.12.036 · Cited by 59
Self-citationLoss of Tenascin-X expression during tumor progression: A new pan-cancer marker
Liot, S., Aubert, A., Hervieu, V., Kholti, N. E., Schalkwijk, J., Verrier, B., Valcourt, U., & Lambert, E. (2020) · Matrix Biology Plus · doi:10.1016/j.mbplus.2020.100021 · Cited by 62
Androgen Receptor-Target Genes in African American Prostate Cancer Disparities
Wang, B., Yang, Q., Ceniccola, K., Bianco, F. J., Andrawis, R., Jarrett, T. W., Frazier, H. A., Patierno, S. R., & Lee, N. H. (2013) · Prostate Cancer · doi:10.1155/2013/763569 · Cited by 62
Validation of proposed prostate cancer biomarkers with gene expression data: a long road to travel
Amaro, A. A., Esposito, A. I., Gallina, A. M., Nees, M., Angelini, G., Albini, A., & Pfeffer, U. (2014) · Cancer and Metastasis Reviews · doi:10.1007/s10555-013-9470-4 · Cited by 65
Su, B., Gao, L., Baranowski, C., Gillard, B. M., Wang, J., Ransom, R., Ko, H., & Gelman, I. H. (2014) · PLoS ONE · doi:10.1371/journal.pone.0101411 · Cited by 61
Role of diet in prostate cancer: the epigenetic link
Labbé, D. P., Zadra, G., Ebot, E. M., Mucci, L. A., Kantoff, P. W., Loda, M. F., & Brown, M. A. (2014) · Oncogene · doi:10.1038/onc.2014.422 · Cited by 64
CSR1 Suppresses Tumor Growth and Metastasis of Prostate Cancer
Yu, G., Tseng, G. C., Yan, Y., Gavel, T., Nelson, J. B., Wells, A. H., Michalopoulos, G. K., Kokkinakis, D., & Luo, J.-H. (2006) · American Journal Of Pathology · doi:10.2353/ajpath.2006.050620 · Cited by 58
Self-citationc-Myc phosphorylation by PKCζ represses prostate tumorigenesis
Kim, J. Y., Valencia, T., Abu‐Baker, S., Linares, J., Lee, S. J., Yajima, T., Chen, J., Eroshkin, A. M., Castilla, E. A., Brill, L. M., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1221799110 · Cited by 57
Jhavar, S. G., Brewer, D. S., Edwards, S. E., Kote‐Jarai, Z., Attard, G., Clark, J., Flohr, P., Christmas, T. J., Thompson, A. C., Parker, M. D., et al. (2008) · British Journal of Urology · doi:10.1111/j.1464-410x.2008.08200.x · Cited by 61
Evaluation of protein biomarkers of prostate cancer aggressiveness
Rizzardi, A. E., Rosener, N. K., Koopmeiners, J. S., Vogel, R. I., Metzger, G. J., Forster, C. L., Marston, L. O., Tiffany, J. R., McCarthy, J. B., Turley, E. A., et al. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-244 · Cited by 57
Munkley, J., McClurg, U. L., Livermore, K. E., Ehrmann, I. E., Knight, B., McCullagh, P. J., McGrath, J. S., Crundwell, M. C., Harries, L. W., Leung, H. Y., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-05489-5 · Cited by 59
Modulation of Androgen Receptor Signaling in Hormonal Therapy-Resistant Prostate Cancer Cell Lines
Marques, R. B., Dits, N. F. J., Erkens‐Schulze, S., van IJcken, W. F. J., van Weerden, W. M., & Jenster, G. W. (2011) · PLoS ONE · doi:10.1371/journal.pone.0023144 · Cited by 56
Yu, Y. P., Ding, Y., Chen, R., Liao, S. G., Ren, B., Michalopoulos, A., Michalopoulos, G. K., Nelson, J. B., Tseng, G. C., & Luo, J. (2013) · American Journal Of Pathology · doi:10.1016/j.ajpath.2013.08.018 · Cited by 56
Self-citationCai, J., Kandagatla, P., Singareddy, R., Kropinski, A., Sheng, S., Cher, M. L., & Chinni, S. R. (2010) · Translational Oncology · doi:10.1593/tlo.09328 · Cited by 61
Interference with HH–GLI signaling inhibits prostate cancer
Stecca, B. A., Mas, C., & Altaba, A. R. I. (2005) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2005.03.004 · Cited by 56
The interplay between AR, EGF receptor and MMP-9 signaling pathways in invasive prostate cancer
Mandel, A., Larsson, P., Sarwar, M., Semenas, J., Khaja, A. S. S., & Persson, J. L. (2018) · Molecular Medicine · doi:10.1186/s10020-018-0035-4 · Cited by 55
Malins, D. C., Gilman, N. K., Green, V. M., Wheeler, T. M., Barker, E. A., & Anderson, K. M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509630102 · Cited by 54
Risk, M. C., Knudsen, B. S., Coleman, I. M., Dumpit, R. F., Kristal, A. R., Meur, N. L., Gentleman, R. C., True, L. D., Nelson, P. S., & Lin, D. W. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0272 · Cited by 54
ksRepo: a generalized platform for computational drug repositioning
Brown, A. S., Kong, S. W., Kohane, I. S., & Patel, C. J. (2016) · BMC Bioinformatics · doi:10.1186/s12859-016-0931-y · Cited by 57
Methylation of the ASC gene promoter is associated with aggressive prostate cancer
Collard, R. L., Harya, N. S., Monzon, F. A., Maier, C., & O’Keefe, D. S. (2006) · The Prostate · doi:10.1002/pros.20371 · Cited by 54
Peng, Y., Liu, J., Wang, Z., Cui, C., Zhang, S., Zhang, S., Gao, P., Hou, Z., Liu, H., Guo, J., et al. (2022) · Cell Death and Differentiation · doi:10.1038/s41418-022-00960-x · Cited by 53
Sapkota, D., Bruland, O., Parajuli, H., Osman, T., Teh, M., Johannessen, A. C., & Costea, D. E. (2015) · BMC Cancer · doi:10.1186/s12885-015-1622-1 · Cited by 53
MAPK/ERK signaling pathway-induced hyper-O-GlcNAcylation enhances cancer malignancy
Zhang, X., Ma, L., Qi, J., Shan, H., Yu, W., & Gu, Y. (2015) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-015-2542-8 · Cited by 54
Markers of Field Cancerization: Proposed Clinical Applications in Prostate Biopsies
Trujillo, K. A., Jones, A. C., Griffith, J. K., & Bisoffi, M. (2012) · Prostate Cancer · doi:10.1155/2012/302894 · Cited by 53
Lu, D., Song, Y., Yu, Y., Wang, D., Liu, B., Chen, L., Li, X., Li, Y., Cheng, L., Lv, F., et al. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-04077-w · Cited by 52
Self-citationGuo, J., Wang, M., & Liu, X. (2015) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-015-0209-7 · Cited by 52
Liver X Receptors Protect from Development of Prostatic Intra-Epithelial Neoplasia in Mice
Pommier, A., Dufour, J., Alves, G., Viennois, É., de Boussac, H., Trousson, A., Volle, D. H., Caira, F., Val, P., Arnaúd, P., et al. (2013) · PLoS Genetics · doi:10.1371/journal.pgen.1003483 · Cited by 52
Kalidindi, T. M., Lee, S. G., Jou, K., Chakraborty, G., Skafida, M., Tagawa, S. T., Bander, N. H., Schöder, H. M., Bodei, L., Pandit-Taskar, N. D., et al. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-05150-w · Cited by 52
Cdc6 and Cyclin E2 Are PTEN-Regulated Genes Associated with Human Prostate Cancer Metastasis
Wu, Z., Cho, H., Hampton, G. M., & Theodorescu, D. (2009) · Neoplasia · doi:10.1593/neo.81048 · Cited by 54
Luo, J., Ding, Y., Chen, R., Michalopoulos, G. K., Nelson, J. B., Tseng, G. C., & Yu, Y. P. (2013) · American Journal Of Pathology · doi:10.1016/j.ajpath.2013.02.040 · Cited by 51
Self-citationAudet-walsh, É., Yee, T., Tam, I. S., & Giguère, V. (2017) · Endocrinology · doi:10.1210/en.2016-1926 · Cited by 45
Hamzeh, O., Alkhateeb, A., Zheng, J., Kandalam, S., & Rueda, L. G. (2020) · BMC Bioinformatics · doi:10.1186/s12859-020-3345-9 · Cited by 51
CSR1 induces cell death through inactivation of CPSF3
Zhu, Z.-H., Yu, Y. P., Shi, Y.-K., Nelson, J. B., & Luo, J.-H. (2008) · Oncogene · doi:10.1038/onc.2008.359 · Cited by 50
Self-citationPio, R., Jia, Z., Baron, V. T., & Mercola, D. (2013) · PLoS ONE · doi:10.1371/journal.pone.0054096 · Cited by 53
Makkonen, H., Jääskeläinen, T. J., Pitkänen-Arsiola, T., Rytinki, M. M., Waltering, K. K., Mättö, M., Visakorpi, T., & Palvimo, J. J. (2008) · Oncogene · doi:10.1038/onc.2008.125 · Cited by 50
Regulation of Androgen-Responsive Transcription by the Chromatin Remodeling Factor CHD8
Menon, T., Yates, J. A., & Bochar, D. A. (2010) · Molecular Endocrinology · doi:10.1210/me.2009-0421 · Cited by 52
miR‐193b promotes cell proliferation by targeting Smad3 in human glioma
Qisheng, Z., Wang, T., Lu, P., Zhang, R., Zou, J., & Yuan, S. (2014) · Journal of Neuroscience Research · doi:10.1002/jnr.23339 · Cited by 49
Sang, M., Hulsurkar, M. M., Zhang, X., Song, H., Zheng, D., Zhang, Y., Li, M., Xu, J., Zhang, S., Ittmann, M., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9359 · Cited by 49
Daly, A. C., Vizán, P., & Hill, C. S. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.043877 · Cited by 49
PPM1A is a RelA phosphatase with tumor suppressor-like activity
Lu, X., An, H., Jin, R., Zou, M., Guo, Y., Su, P.-F., Liu, D., Shyr, Y., & Yarbrough, W. G. (2013) · Oncogene · doi:10.1038/onc.2013.246 · Cited by 49
Yu, Y. P., Paranjpe, S., Nelson, J. B., Finkelstein, S. D., Ren, B., Kokkinakis, D. M., Michalopoulos, G. K., & Luo, J. (2004) · Carcinogenesis · doi:10.1093/carcin/bgh310 · Cited by 49
Self-citationNUSAP1 expression is upregulated by loss of RB1 in prostate cancer cells
Gordon, C. A., Gulzar, Z. G., & Brooks, J. D. (2015) · The Prostate · doi:10.1002/pros.22938 · Cited by 48
Multiple Oncogenic Pathway Signatures Show Coordinate Expression Patterns in Human Prostate Tumors
Creighton, C. J. (2008) · PLoS ONE · doi:10.1371/journal.pone.0001816 · Cited by 48
A genome-wide integrative study of microRNAs in human liver
Gamazon, E. R., Innocenti, F., Wei, R., Wang, L., Zhang, M., Mirkov, S., Ramírez, J., Huang, R. S., Cox, N. J., Ratain, M. J., et al. (2013) · BMC Genomics · doi:10.1186/1471-2164-14-395 · Cited by 48
A Role for Androgens in Epithelial Proliferation and Formation of Glands in the Mouse Uterus
Simitsidellis, I., Gibson, D. A., Cousins, F. L., Esnal‐Zufiaurre, A., & Saunders, P. T. K. (2016) · Endocrinology · doi:10.1210/en.2015-2032 · Cited by 51
Identification of potential therapeutic targets in prostate cancer through a cross‐species approach
Jurmeister, S., Ramos‐Montoya, A., Sandi, C., Pértega‐Gomes, N., Wadhwa, K., Lamb, A. D. G., Dunning, M., Attig, J., Carroll, J. S., Fryer, L. G. D., et al. (2018) · EMBO Molecular Medicine · doi:10.15252/emmm.201708274 · Cited by 49
Snail1 is over‐expressed in prostate cancer
Heebøll, S., Borre, M., Ottosen, P. D., Dyrskjøt, L., Orntoft, T. F., & Tørring, N. (2009) · Apmis · doi:10.1111/j.1600-0463.2008.00007.x · Cited by 48
Oncogenic Activity of miR-650 in Prostate Cancer Is Mediated by Suppression of CSR1 Expression
Zuo, Z., Yu, Y. P., Ding, Y., Liu, S., Martin, A., Tseng, G. C., & Luo, J. (2015) · American Journal Of Pathology · doi:10.1016/j.ajpath.2015.03.015 · Cited by 48
Self-citationShiota, M., Yokomizo, A., Fujimoto, N., & Naito, S. (2011) · Current Cancer Drug Targets · doi:10.2174/156800911796798904 · Cited by 49
RasGRP3 Contributes to Formation and Maintenance of the Prostate Cancer Phenotype
Yang, D., Kedei, N., Li, L., Tao, J., Velasquez, J. F., Michalowski, A. M., Tóth, B. I., Marincsák, R., Varga, A., Bíró, T., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4729 · Cited by 47
Knockdown of AGR2 induces cellular senescence in prostate cancer cells
Hu, Z., Gu, Y., Han, B., Zhang, J., Li, Z., Tian, K., Young, C. Y. F., & Yuan, H. (2012) · Carcinogenesis · doi:10.1093/carcin/bgs141 · Cited by 49
Chen, C., Cai, Q., He, W., Lam, T. B. L., Lin, J., Zhao, Y., Chen, X., Gu, P., Huang, H., Xue, M., et al. (2017) · Cell Death and Disease · doi:10.1038/cddis.2017.437 · Cited by 51
Cooper, C. S., Campbell, C., & Jhavar, S. G. (2007) · Nature Clinical Practice Urology · doi:10.1038/ncpuro0946 · Cited by 47
ETS variant 1 regulates matrix metalloproteinase-7 transcription in LNCaP prostate cancer cells
Shin, S., Oh, S., AN, S., & Janknecht, R. (2012) · Oncology Reports · doi:10.3892/or.2012.2079 · Cited by 47
Murph, M. M., Nguyen, G. H., Radhakrishna, H., & Mills, G. B. (2008) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2008.04.007 · Cited by 47
A Novel Gene Signature for Molecular Diagnosis of Human Prostate Cancer by RT-qPCR
Rizzi, F., Belloni, L., Crafa, P., Lazzaretti, M., Remondini, D., Ferretti, S., Cortellini, P., Corti, A., & Bettuzzi, S. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003617 · Cited by 47
Hornstein, M., Hoffmann, M. J., Alexa, A., Yamanaka, M., Müller, M., Jung, V., Rahnenführer, J., & Schulz, W. A. (2008) · PubMed · Cited by 47
Villar, J., Arenas, M. I., MacCarthy, C. M., Blánquez, M. J., Tirado, Ò. M., & Notario, V. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2041 · Cited by 55
Changes in PKM2 Associate with Prostate Cancer Progression
Wong, N., Yan, J., Ojo, D., Melo, J. D., Cutz, J., & Tang, D. (2014) · Cancer Investigation · doi:10.3109/07357907.2014.919306 · Cited by 46
Rice, M. A., Ishteiwy, R., Magani, F., Udayakumar, T. S., Reiner, T., Yates, T. J., Miller, P., Perez‐Stable, C., Rai, P., Verdún, R. E., et al. (2016) · Oncogene · doi:10.1038/onc.2016.6 · Cited by 52
The SOX4/miR-17-92/RB1 Axis Promotes Prostate Cancer Progression
Liu, H., Wu, Z., Zhou, H., Cai, W., Li, X., Hu, J., Gao, L., Feng, T., Wang, L., Peng, X., et al. (2019) · Neoplasia · doi:10.1016/j.neo.2019.05.007 · Cited by 46
Self-citationKokontis, J. M., Lin, H., Jiang, S. S., Lin, C., Fukuchi, J., Hiipakka, R. A., Chung, C., Chan, T.-M., Liao, S., Chang, C., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0109170 · Cited by 45
Bi-correlation clustering algorithm for determining a set of co-regulated genes
Bhattacharya, A., & De, R. K. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp526 · Cited by 45
Nalla, A. K., Williams, T. F., Collins, C. P., Rae, D. T., & Trobridge, G. D. (2015) · Molecular Carcinogenesis · doi:10.1002/mc.22425 · Cited by 45
Expression of the actin-associated protein transgelin (SM22) is decreased in prostate cancer
Prasad, P. D., Stanton, J. L., & Assinder, S. J. (2009) · Cell and Tissue Research · doi:10.1007/s00441-009-0902-y · Cited by 45
Context‐specific protein tyrosine kinase 6 ( PTK 6) signalling in prostate cancer
Zheng, Y., & Tyner, A. L. (2013) · European Journal of Clinical Investigation · doi:10.1111/eci.12050 · Cited by 45
Marked Gene Transcript Level Alterations Occur Early During Radical Prostatectomy
Schlomm, T., Näkel, E., Lübke, A. M., Buneß, A., Chun, F. K. ‐., Steuber, T. P., Graefen, M., Simon, R., Sauter, G., Poustka, A., et al. (2007) · European Urology · doi:10.1016/j.eururo.2007.03.075 · Cited by 47
SPARCL1 suppresses metastasis in prostate cancer
Xiang, Y., Qiu, Q., Jiang, M., Jin, R., Lehmann, B. D., Strand, D. W., Jovanović, B., DeGraff, D. J., Zheng, Y., Yousif, D. A., et al. (2013) · Molecular Oncology · doi:10.1016/j.molonc.2013.07.008 · Cited by 44
Transcriptional Regulation of CXCR4 in Prostate Cancer: Significance of TMPRSS2-ERG Fusions
Singareddy, R., Semaan, L., Conley‐LaComb, M. K., John, J. S., Powell, K., Iyer, M. K., Smith, D. W., Heilbrun, L. K., Shi, D., Sakr, W., et al. (2013) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-12-0705 · Cited by 44
AIM1 is an actin-binding protein that suppresses cell migration and micrometastatic dissemination
Haffner, M. C., Esopi, D., Chaux, A., Gürel, M., Ghosh, S., Vaghasia, A. M., Tsai, H. K., Kim, K., Castagna, N., Lam, H., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00084-8 · Cited by 47
Kamdar, S. N., Isserlin, R., van der Kwast, T., Zlotta, A. R., Bader, G. D., Fleshner, N. E., & Bapat, B. V. (2019) · Clinical Epigenetics · doi:10.1186/s13148-019-0651-z · Cited by 44
Heterogeneous epigenetic regulation ofTIMP3in prostate cancer
Shinojima, T., Yu, Q., Huang, S. K., Li, M., Mizuno, R., Liu, E. T., Hoon, D. S. �., & Lessard, L. (2012) · Epigenetics · doi:10.4161/epi.22333 · Cited by 43
Song, K. W., Wang, H., Krebs, T. L., Wang, B., Kelley, T. J., & Danielpour, D. (2010) · Molecular Endocrinology · doi:10.1210/me.2010-0165 · Cited by 43
The role of ATP‐binding cassette transporter genes in the progression of prostate cancer
Karataş, Ö. F., Güzel, E., Düz, M. B., Ittmann, M., & Özen, M. (2015) · The Prostate · doi:10.1002/pros.23137 · Cited by 43
The discovery and application of gene fusions in prostate cancer
Morris, D. S., Tomlins, S. A., Montie, J. E., & Chinnaiyan, A. M. (2008) · British Journal of Urology · doi:10.1111/j.1464-410x.2008.07665.x · Cited by 43
Farrall, A. L., & Whitelaw, M. L. (2009) · Oncogene · doi:10.1038/onc.2009.228 · Cited by 48
Osteoprotegerin in Bone Metastases: Mathematical Solution to the Puzzle
Ryser, M. D., Qu, Y., & Komarova, S. V. (2012) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1002703 · Cited by 43
Richiardi, L., Fiano, V., Grasso, C., Zugna, D., Delsedime, L., Gillio‐Tos, A., & Merletti, F. (2013) · PLoS ONE · doi:10.1371/journal.pone.0068162 · Cited by 42
Bergström, S. H., Hammarsten, P., Adamo, H. H., Wikström, P., & Bergh, A. R. J. (2010) · Expert Opinion on Medical Diagnostics · doi:10.1517/17530059.2011.540009 · Cited by 42
Sun, R., Fu, X., Li, Y., Xie, Y., & Mao, Y. (2009) · BMC Genomics · doi:10.1186/1471-2164-10-93 · Cited by 46
Zhou, H., Mazan-Mamczarz, K., Martindale, J. L., Barker, A. J., Liu, Z., Gorospe, M., Leedman, P. J., Gartenhaus, R. B., Hamburger, A. W., & Zhang, Y. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq084 · Cited by 42
Redmer, T., Raigel, M., Sternberg, C., Ziegler, R., Probst, C., Lindner, D., Aufinger, A., Limberger, T., Trachtová, K., Kodajova, P., et al. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02022-x · Cited by 42
PRK1/PKN1 controls migration and metastasis of androgen-independent prostate cancer cells
Jilg, C. A., Ketscher, A., Metzger, E., Hummel, B., Willmann, D., Rüsseler, V., Drendel, V., Imhof, A., Jung, M., Franz, H., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2653 · Cited by 41
Loss of EGR3 is an independent risk factor for metastatic progression in prostate cancer
Shin, S.-H., Kim, I., Lee, J. E., Lee, M., & Park, J. (2020) · Oncogene · doi:10.1038/s41388-020-01418-5 · Cited by 50
Wenta, T., Schmidt, A., Zhang, Q., Devarajan, R., Singh, P., Yang, X., Ahtikoski, A. M., Vaarala, M. H., Wei, G., & Manninen, A. (2022) · Oncogene · doi:10.1038/s41388-022-02389-5 · Cited by 44
Potential role of EPB41L3 (Protein 4.1B/Dal-1) as a target for treatment of advanced prostate cancer
Bernkopf, D. B., & Williams, E. D. (2008) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.12.7.845 · Cited by 41
Mostaghel, E. A., Geng, L. N., Holcomb, I. N., Coleman, I. M., Lucas, J. M., True, L. D., & Nelson, P. S. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2509 · Cited by 44
Genome Abnormalities Precede Prostate Cancer and Predict Clinical Relapse
Yu, Y. P., Song, C. W., Tseng, G. C., Ren, B., LaFramboise, W. A., Michalopoulos, G. K., Nelson, J. B., & Luo, J. (2012) · American Journal Of Pathology · doi:10.1016/j.ajpath.2012.03.008 · Cited by 40
Self-citation
Metadata
- Authors
- Yu, Y. P., Landsittel, D., Jing, L., Nelson, J., Ren, B., Liu, L., McDonald, C., Thomas, R., Dhir, R., Finkelstein, S., Michalopoulos, G., Becich, M., & Luo, J.-H.
- Affiliations
- University of Pittsburgh (US)
- From the Department of Pathology and Urology, University of Pittsburgh School of Medicine, and Biostatistics Center, University of Pittsburgh Cancer Institute and Department of Biostatistics, University of Pittsburgh, Pittsburgh, PA
- ORCID
- Venue
- Journal of Clinical Oncology
- Published
- 2004-07-15
- Volume
- 22
- Issue
- 14
- Pages
- 2790-2799
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2108426942
- Semantic Scholar
- 8be3bd0e253d2a736b72002f40143dec896e862a
- Cited by
- 758
- References
- 23
- Citations by year
- 2026: 12 · 2025: 9 · 2024: 31 · 2023: 31 · 2022: 20 · 2021: 30 · 2020: 26 · 2019: 29 · 2018: 29 · 2017: 38 · 2016: 24 · 2015: 47 · 2014: 58 · 2013: 41 · 2012: 47
- FWCI
- 10.59
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Clinical Oncology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (U01CA088110, 1U01 CA 88110-01, R01CA098249)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gene expression and cancer classification
- Keywords
- prostate cancer, gene expression profiling, tumor aggressiveness, prostate carcinogenesis, gene expression patterns
- MeSH terms
- Adult, Cell Transformation, Neoplastic, Humans, Male, Middle Aged, Neoplasm Invasiveness, Predictive Value of Tests, Prostate, Prostatic Neoplasms, Gene Expression, Disease Progression, Oligonucleotide Array Sequence Analysis, Gene Expression Profiling
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.